Analysts expect that CareDx, Inc. (NASDAQ:CDNA) will announce sales of $11.86 million for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for CareDx’s earnings. The highest sales estimate is $12.08 million and the lowest is $11.65 million. CareDx posted sales of $10.71 million in the same quarter last year, which would indicate a positive year over year growth rate of 10.7%. The business is expected to announce its next quarterly earnings report on Wednesday, August 9th.

On average, analysts expect that CareDx will report full year sales of $11.86 million for the current financial year. For the next financial year, analysts anticipate that the firm will post sales of $55.20 million per share. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow CareDx.

CDNA has been the topic of a number of recent analyst reports. ValuEngine lowered CareDx from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Zacks Investment Research upgraded CareDx from a “hold” rating to a “buy” rating and set a $1.25 price objective on the stock in a research report on Friday, June 9th.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/06/25/11-86-million-in-sales-expected-for-caredx-inc-cdna-this-quarter.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CDNA. Armstrong Henry H Associates Inc. purchased a new position in CareDx during the first quarter worth approximately $22,450,000. Royce & Associates LP boosted its position in CareDx by 72.2% in the fourth quarter. Royce & Associates LP now owns 426,361 shares of the company’s stock worth $1,151,000 after buying an additional 178,743 shares during the last quarter. Finally, Gagnon Securities LLC boosted its position in CareDx by 12.8% in the first quarter. Gagnon Securities LLC now owns 2,026,338 shares of the company’s stock worth $2,837,000 after buying an additional 230,494 shares during the last quarter. Institutional investors own 36.52% of the company’s stock.

CareDx (NASDAQ CDNA) opened at 1.08 on Friday. The firm has a 50-day moving average price of $1.04 and a 200 day moving average price of $1.85. CareDx has a 52 week low of $0.76 and a 52 week high of $5.09. The firm’s market capitalization is $23.13 million.

CareDx Company Profile

CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.

Get a free copy of the Zacks research report on CareDx (CDNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CareDx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.